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Edited by Gerrit van MeerAbstract Bilayers made of dioleoylphosphatidylcholine
(DOPC)/dipalmitoylphosphatidylcholine (DPPC) mixture con-
taining or not cholesterol (Chl) were used to investigate the
interaction of a carrier peptide with membranes. Atomic force
microscopy revealed that the C-terminal 9-32 fragment of human
calcitonin (hCT (9-32)), free or coupled to enhanced green
ﬂuorescent protein (hCT-eGFP) cargo forms aggregates in the
DOPC ﬂuid phase in absence of Chl and in the DPPC enriched
liquid-ordered phase when Chl is present. The data show that
hCT (9-32) plays a determinant role in the membrane localiza-
tion of the peptide–cargo complex. They suggest that carpet-like
mechanism for membrane destabilization may be involved in the
carrier function of hCT (9-32).
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Cell membrane carrier peptides, also called cell penetrating
peptides (CPPs), deliver large hydrophilic molecules (cargo)
like proteins or nucleotides to the intracellular space. The low
lytic activity and high eﬃciency characterizing these CPPs
explain they appear as promising tools in the ﬁeld of drug and
gene therapy [1–3]. The mechanisms involved in the peptide/
cargo translocation across cells plasma membrane however
remain a matter of debates. Thus, it is not clear to what extent
some of the peptides require energy for cell entering [4–6].
According to the peptides, they might form carpet-like struc-
tures that destabilize the bilayer organization allowing the
intracellular delivery of the cargo or induce the formation of
transient pores [7–9]. How large hydrophilic cargo molecules
linked to peptides aﬀect the peptide–membrane interaction is
also poorly understood.
Human calcitonin peptide C-terminal fragment 9-32 (hCT
(9-32)) derived from the human calcitonin hormone (hCT) was
shown to translocate cargo across cells membrane by a path-
way which does not involve the hormone receptor [10,11].* Corresponding author. Fax: +33-467- 41-79-13.
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the enhanced green ﬂuorescent protein (eGFP) into excised
nasal mucosa [12]. It is also known that hCT induces the
formation of voltage-dependent channels in lipid bilayers [13].
In order to better characterize the mechanisms involved in
hCT (9-32) carrier activity we have added the peptide and the
peptide–eGFP complex to dioleoylphosphatidylcholine
(DOPC)/dipalmitoylphosphatidylcholine (DPPC) (1:1) sup-
ported bilayers containing or not cholesterol (Chl). In this
study, care was taken to add the peptide under conditions as
close as possible to those for delivery of cargo into the cells.
Atomic force microscopy (AFM) was used to characterize the
surface topography of samples. AFM was previously shown to
provide unique information on lipid–peptide interactions in
both monolayers and supported bilayers [14–16].2. Materials and methods
2.1. Materials
hCT (9-32) fragment. The peptide 9-32, fragment of human calci-
tonin (hCT), has the following sequence: L9GTYTQDF16NKFHT-
FP23QTAIGVGAP32-NH2. It was synthesized by automated multiple
solid-phase peptide synthesis (Fmoc strategy) using a robot system
(Syro, MultiSynTech, Bochum, Germany) as previously described [12].
The peptide was analysed by RP HPLC and matrix assisted laser de-
sorption ionisation (MALDI) mass spectrometry. Correct mass was
found at 2610.0 (calc. 2608.3) and purity according to HPLC was
>96%.
hCT (9-32)/eGFP complex. eGFP is a 239 amino acid red-shifted
variant of wild-type GFP that has been optimized for brighter ﬂuo-
rescence and higher expression in mammalian cells. Expressed protein
ligation was used to generate a construct of recombinant eGFP and the
amidated hCT-derived peptide [12]. Ligation was performed by a
chemical ligation strategy [17].
2.2. Methods
Preparation of supported bilayers. Supported bilayers made of
DOPC/DPPC (1:1) and DOPC/DPPC/Chl (1:1:0.35) mixtures (Sigma–
Aldrich, Saint Quentin-Fallavier, France) were formed from multila-
mellar vesicles (MLVS) as previously described [18]. The MLVs
suspension (0.3 mM) was extruded at 65 C through 0.1 lm pore
diameter polycarbonate membranes (Avanti Polar Lipids, Alabaster,
AL) to obtain unilamellar vesicles. The vesicles suspension was de-
posited on a freshly cleaved mica surface and incubated, without ex-
posure to air, at 65 C for 2 h in a water bath. At the end of the
incubation, the bilayers were rinsed with PBS to remove the vesicles in
excess.
Atomic force microscopy. AFM observations of the bilayers were
performed as previously described [15,18] on a Nanoscope IIIA
(Digital Instruments, Santa Barbara, CA) equipped with a ﬂuid cell,ation of European Biochemical Societies.
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contact mode. Topographic (height) images were acquired in constant-
force mode using silicon nitride tips on cantilevers with a nominal
spring constant of 0.03 N/m (Park Scientiﬁc Instruments, Sunnyvale,
CA), at a scan rate of 1 Hz. Typically, the scanning force was adjusted
to below 0.2 nN and readjusted for drift during images acquisition.
Images were obtained from at least two diﬀerent samples for each
condition with at least three macroscopically separated areas on each
sample. Representative height images are presented.
Incubation of bilayers with hCT (9-32). Samples were ﬁrst checked
for the quality of the supported bilayers before addition of hCT (9-32).
To avoid contamination of the AFM liquid cell by the peptide, samples
were taken out of the microscope and incubated at room temperature
for various times from 30 min to 18 h, according to the bilayer com-
position, with 150 ll of 50 lM hCT (9-32) (or hCT (9-32)/eGFP). Such
a concentration is needed for hCT (9-32) acting as a carrier peptide on
living cells [11,12]. At the end of the incubation period, the bilayer was
rinsed with PBS at pH 7.4 and placed under the microscope.3. Results
3.1. hCT 9-32 interaction with ﬂuid-gel phase separated bilayers
As previously reported [18], AFM examination in buﬀer of
DOPC/DPPC (1:1) revealed the presence at room temperature
of DPPC-enriched gel domains up to several lm in size which
protrude by 1.0± 0.1 nm from the smooth DOPC matrix
(Fig. 1A). Following 150 min incubation with 50 lM hCT (9-
32), a concentration used for peptide/cargo internalization by
cells culture, the most striking topography change at low
magniﬁcation concerned the DOPC matrix aspect which be-
came grainy (Fig. 1B). No detectable change in the roughness
and in the size of gel phase DPPC domains could be observed.Fig. 1. Formation of hCT (9-32) aggregates in the DOPC enriched
ﬂuid phase. Upon addition of hCT (9-32) to DOPC/DPPC (1:1) sup-
ported bilayers (A), the darker ﬂuid phase is covered with brigth dots
(B). Peptide aggregates resist to successive scans of the same zone (C,
D, arrows). Higher magniﬁcation reveals the globular shape of ag-
gregates (E). AFM height images in buﬀer. Scan size: 10 lm (A, B),
5 lm (C, D), 2.5 lm (E).
Fig. 2. Flat domain-like structures (arrows) decorate the bilayer ﬂuid
phase upon long duration incubation with hCT (9-32) (A, B). Peptide
aggregates (arrow heads) are also visualized at the surface of gel do-
mains. C is a virtual section of B. Scan size: 10 lm (A) and 2.5 lm (B).Examination of samples at a higher magniﬁcation (Fig. 1C)
revealed that the grainy aspect of the ﬂuid phase was due to the
presence of numerous globular aggregates, practically exclu-
sively localized in the DOPC matrix, with no globular struc-
tures accumulated on the gel phase or at the ﬂuid-gel interface.
Except for a few large (300–500 nm) and tall (up to 15 nm)
patches, the globular structures consisted of aggregates 76 10
nm in diameter protruding from the matrix with 1.5 nm
maximum height. Aggregates were still present upon successive
scans of the same zone (Figs. 1C and D, arrows) which indi-
cates their anchoring resisted to the friction forces associated
with scanning. Under identical incubation conditions, no
348 S. Boichot et al. / FEBS Letters 569 (2004) 346–350aggregates could be detected at the surface of bare mica (data
not shown). Increasing the incubation time up to 16–18 h, the
ﬂuid phase matrix was markedly modiﬁed, and more diﬃcult
to discern from the gel phase at low magniﬁcation (Fig. 2):
hCT (9-32) aggregates assembled to form domains-like struc-
ture, up to 300 nm in length, protruding by 1–2 nm above the
DOPC ﬂuid phase (Fig. 2B, arrows). For these long incubation
periods, peptide aggregates of comparable size and up to 5 nm
in height (Fig. 2C) decorated the gel phase domains (arrow-
heads). Brighter spots likely corresponding to surface con-
taminants were often observed following long duration
incubations.
3.2. hCT (9-32)/eGFP cargo complexes localize in the
DOPC/DPPC bilayer ﬂuid phase
Contrasting with the results obtained for the peptide alone,
incubation of hCT (9-32)/eGFP complex resulted in a signiﬁ-
cant and random adsorption of aggregates 50–90 nm in di-
ameter at the surface of bare mica (Fig. 3A). Adding the
complex to the DOPC/DPPC supported bilayers for 150 min
induced a large modiﬁcation of the ﬂuid phase, leaving the gel
phase unchanged (Fig. 3B). As compared to images obtained
at identical magniﬁcation when incubating with the peptide
alone, the ﬂuid phase was characterized by the presence of
many microdomain-like patches in addition to the small
globular structures (Fig. 3C arrowheads). Reducing the scanFig. 3. hCT (9-32)/eGFP complex forms aggregates which adhere on mica sur
(arrowheads) and clusters of aggregates organized into domains (arrows) are
5 lm (C). Domains of aggregates are still preferentially localized in the ﬂuid
the gel phase (large arrow head) following long-time (16–18 h) exposure (D
pierced by holes (thin arrow heads). Scan size: 5 lm (D), 3.4 lm (E), 2 lmsize showed that microdomains-like patches consisted of
clustered globular aggregates (62 10 nm in diameter) which
protruded 4 nm from the ﬂuid phase (Fig. 3C, arrows). They
were often surrounded by a boundary emerging 0.6 nm from
the DOPC enriched ﬂuid phase. At low magniﬁcation, the
most striking changes in the topography of the bilayer, fol-
lowing 16–18 h incubations, were the clustering of hCT (9-32)/
eGFP complexes, essentially in DOPC enriched ﬂuid phase
(Fig. 3D, arrows), with a few clusters present either at the
ﬂuid-gel phase boundary or on the gel phase domains (Figs.
3D and E, large arrowheads). Zones of the ﬂuid phase bilayer
appeared destabilized, being made of small and rough irregular
microdomains 20–50 nm in length (Fig. 3D, thin arrows)
eventually pierced by holes 50–140 nm in diameter (thin ar-
rowheads).
3.3. Eﬀect of cholesterol on hCT (9-32) and hCT (9-32)/eGFP
cargo distribution
By inducing the formation of a liquid-ordered (lo) phase that
separates from the ﬂuid phase, Chl plays a determinant role in
the formation of microdomains in the plasma membrane of
mammalian cells [19]. Addition of Chl to the DOPC/DPPC
mixture resulted in the branching of the DPPC–Chl enriched lo
ordered domains (Fig. 4A), as previously reported [20]. The
presence of Chl was associated with an enhanced sensitivity of
bilayers to the peptide imposing a reduction in the incubationface (A, scan size 2.5 lm). After 2 h and 30 min incubation, aggregates
exclusively found in the bilayer ﬂuid phase (B, C). Scan size: 10 lm (B),
phase (large arrows) but some are found at the phases boundary or on
–F). By place, the ﬂuid phase appears disorganised (thin arrows) and
(F).
Fig. 4. Addition of Chl (DOPC/DPPC/Chl, 1:1:0.35) induces the formation of branched domains enriched in liquid-ordered lipids (A, scan size 5 lm).
After 30 min incubation with hCT (9-32), the branched domains network is disorganized and disappears (arrowheads) in the vicinity of large ag-
gregates of peptide (B, C, arrows). Scan size: 5 lm (B), 2.5 lm (C). Upon incubation with hCT (9-32)/eGFP complex for the same time, the bilayer
topography is markedly modiﬁed (D, scan size 5 lm). Aggregates of hCT (9-32)/eGFP complexes are essentially found in the ordered phase domains
(D, E, arrows) which are partly disrupted (thin arrows). Scan size (E): 2.5 lm.
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form domains-like structure up to 600 nm in size generally
pierced by large holes that perforate the bilayer (Figs. 4B and
C, arrows). The aggregates were surrounded by a zone poor in
lo enriched domains (Figs. 4B and C, arrowheads) which
strongly suggested the peptide had primarily interacted with
and disrupted the branched domains. This view was supported
by the perturbed organization of the branched network at a
longer distance. In accordance with Chl-free samples, incuba-
tion with hCT (9-32)/eGFP complexes had a more marked
eﬀect on the bilayer topography. Branched domains were re-
placed by larger disconnected domains (Figs. 4D and E). Ag-
gregates of hCT (9-32)/eGFP complexes were found practically
exclusively on the lo-enriched domains (arrows) where large
holes were also frequently observed (thin arrows).4. Discussion
4.1. hCT (9-32) forms aggregates whose localization depends
on lipid composition
The data show that, under concentrations conditions re-
quired for the carrier peptide eﬃciency in cells, hCT (9-32)
preferentially anchors either in the ﬂuid or in the liquid-or-
dered phase of phase separated supported phosphatidylcholine
bilayer, according to the presence of Chl. It is worth notingthat with hCT (9-32) concentration 10 times lower, no modi-
ﬁcation of the bilayer topography could be noticed (data not
shown). These data are in agreement with those obtained for
salmon calcitonin where the peptide interacts with zwitterionic
phospholipids only at high concentrations [21]. The C-terminal
part of hCT plays an essential role in its carrier properties most
likely via a conformational change in the presence of phos-
pholipids, which could also induce the peptide self-assembly
and interaction with the hydrophobic part of membranes [10].
The present observation of hCT (9-32) aggregates at the bi-
layers surface, whose size signiﬁcantly increased as a function
of time in DOPC/DPPC samples, strongly supports this
hypothesis.
In absence of Chl, peptide aggregates were exclusively found
in the bilayer ﬂuid phase and no peptide accumulation at do-
main boundaries occurred, excepted for long-time exposures.
On the other hand, the data suggested a preferential interac-
tion of hCT (9-32) with the liquid-ordered phase in Chl con-
taining bilayers. Such a redistribution was unexpected as
regards to the literature which reports on preferential locali-
zation of transmembrane-a helical peptides [22,23] and am-
phipathic helical membrane active peptides [24] in the ﬂuid
phase of bilayers, even in the presence of Chl. A possible ex-
planation to this behavior, which could also account for the
associated marked increase in the sensitivity of membranes to
the peptide deleterious eﬀect, is that the presence of Chl in
350 S. Boichot et al. / FEBS Letters 569 (2004) 346–350ordered domains favored hCT (9-32) to adopt a diﬀerent
structure. Such a situation is found for amphipathic antimi-
crobial peptides which adopt a-helical, b-sheet, or both a-he-
lical and b-sheet structures [25], with a structure-dependent
lytic eﬀect [26].
4.2. Peptide-dependent localization of hCT(9-32)/eGFP
complexes in bilayers
Imaging of hCT (9-32)/eGFP complexes in buﬀer revealed
the presence of aggregates distributed at random at the surface
of bare mica. As compared to hCT (9-32) alone, this indicated
a signiﬁcant increase in the hydrophilic interaction between
mica and complexes, which can be explained by the presence of
the protein. Conversely, existence of aggregates in buﬀer
should result from hydrophobic-driven self assembly of the
peptide part of complexes. As for the peptide alone, hCT (9-
32)/eGFP aggregates were localized exclusively in the ﬂuid
phase of the DOPC/DPPC bilayers, on the shorter incubation
times, and in the ordered phase of DOPC/DPPC/Chl bilayers.
This demonstrates that hCT (9-32) is capable to address the
complex to speciﬁc regions of a bilayer. Incubation with hCT
(9-32)/eGFP favored the formation of the microdomains-like
patches. Although AFM does not allow to establish the local
composition of these patches, i.e., peptide–peptide vs lipid–
peptide, their size up to a few hundred nm suggests they can
contain at least hundreds of peptide molecules (the molecular
area of hCT (9-32) is close to 5 nm2, unpublished data). This
topography of peptide-treated bilayers suggests that hCT (9-
32) CPP function may involve the carpet-like/toroidal pore
mechanism proposed for antimicrobial peptides [8,9,25]. In
this mechanism, peptides insert in the polar headgroups region
thus creating a membrane thinning which ﬁnally induces
transient defects or pores formation (see Fig. 3 in [25] for
an illustration of the model). Moreover, peptide aggregation
plays a major role in the formation of membrane defects
[25]. Membrane destabilization, associated with the presence
of holes in the bilayer perturbed regions, supports this
hypothesis.
4.3. Concluding remarks
The modiﬁcations in the bilayer organization by hCT (9-
32) and hCT (9-32)/eGFP were obtained using concentra-
tions needed for their transport across cell membranes. This
suggests that peptide aggregates-plasma membrane lipid in-
teractions are involved in the carrier function of the pep-
tide. Both the localization of the peptide–cargo complex,
driven by the peptide part, and the time course of the in-
teraction depend on the membrane lipid composition which
might contribute to the selective activity of hCT (9-32) to-
wards diﬀerent cells.Acknowledgements: This work was supported by the EU Grant QLK2-
2001-01451.References
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